X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs AUROBINDO PHARMA - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES AUROBINDO PHARMA PIRAMAL ENTERPRISES/
AUROBINDO PHARMA
 
P/E (TTM) x 9.5 18.1 52.6% View Chart
P/BV x 1.6 4.6 36.0% View Chart
Dividend Yield % 1.0 0.3 290.1%  

Financials

 PIRAMAL ENTERPRISES   AUROBINDO PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-18
AUROBINDO PHARMA
Mar-17
PIRAMAL ENTERPRISES/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs3,083895 344.5%   
Low Rs1,902622 305.8%   
Sales per share (Unadj.) Rs589.7254.6 231.6%  
Earnings per share (Unadj.) Rs284.039.3 723.1%  
Cash flow per share (Unadj.) Rs310.546.6 666.7%  
Dividends per share (Unadj.) Rs25.002.50 1,000.0%  
Dividend yield (eoy) %1.00.3 304.3%  
Book value per share (Unadj.) Rs1,467.0160.0 917.1%  
Shares outstanding (eoy) m180.27585.88 30.8%   
Bonus/Rights/Conversions ISESOP-  
Price / Sales ratio x4.23.0 141.9%   
Avg P/E ratio x8.819.3 45.4%  
P/CF ratio (eoy) x8.016.3 49.3%  
Price / Book Value ratio x1.74.7 35.8%  
Dividend payout %8.86.4 138.3%   
Avg Mkt Cap Rs m449,332444,390 101.1%   
No. of employees `0006.814.0 48.9%   
Total wages/salary Rs m19,88117,678 112.5%   
Avg. sales/employee Rs Th15,535.610,667.8 145.6%   
Avg. wages/employee Rs Th2,905.41,264.3 229.8%   
Avg. net profit/employee Rs Th7,482.51,645.8 454.6%   
INCOME DATA
Net Sales Rs m106,310149,157 71.3%  
Other income Rs m2,5951,159 223.9%   
Total revenues Rs m108,906150,316 72.5%   
Gross profit Rs m51,59934,343 150.2%  
Depreciation Rs m4,7734,276 111.6%   
Interest Rs m29,783667 4,463.9%   
Profit before tax Rs m19,63830,558 64.3%   
Minority Interest Rs m2,80150 5,579.5%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-28,7647,597 -378.7%   
Profit after tax Rs m51,20323,012 222.5%  
Gross profit margin %48.523.0 210.8%  
Effective tax rate %-146.524.9 -589.2%   
Net profit margin %48.215.4 312.2%  
BALANCE SHEET DATA
Current assets Rs m118,15492,062 128.3%   
Current liabilities Rs m462,26066,223 698.0%   
Net working cap to sales %-323.717.3 -1,868.5%  
Current ratio x0.31.4 18.4%  
Inventory Days Days27106 25.1%  
Debtors Days Days4768 68.8%  
Net fixed assets Rs m113,72762,919 180.8%   
Share capital Rs m361586 61.5%   
"Free" reserves Rs m264,09393,133 283.6%   
Net worth Rs m264,45493,719 282.2%   
Long term debt Rs m242,2061,814 13,352.0%   
Total assets Rs m726,834162,494 447.3%  
Interest coverage x1.746.8 3.5%   
Debt to equity ratio x0.90 4,731.8%  
Sales to assets ratio x0.10.9 15.9%   
Return on assets %11.114.6 76.5%  
Return on equity %19.424.6 78.9%  
Return on capital %10.332.7 31.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,11075,838 19.9%   
Fx outflow Rs m4,29830,224 14.2%   
Net fx Rs m10,81345,613 23.7%   
CASH FLOW
From Operations Rs m-159,66632,786 -487.0%  
From Investments Rs m-17,677-17,870 98.9%  
From Financial Activity Rs m186,503-19,153 -973.8%  
Net Cashflow Rs m9,364-4,239 -220.9%  

Share Holding

Indian Promoters % 52.9 54.1 97.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 8.0 50.3%  
FIIs % 26.6 27.7 96.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 10.2 161.8%  
Shareholders   93,274 69,601 134.0%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   DR. REDDYS LAB  STERLING BIOTECH  JUBILANT LIFE SCIENCES  VENUS REMEDIES  IPCA LABS  

Compare PIRAMAL ENTERPRISES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Sell-Off; Sensex Slumps Over 530 Points(Closing)

Share markets in India continued their sell-off seen during the last week and ended the day deep in the red. All sectoral indices traded on a negative note.

Related Views on News

BIRLA CORP Plunges by 6%; BSE 500 Index Down 1.4% (Market Updates)

Sep 24, 2018 | Updated on Sep 24, 2018

BIRLA CORP share price has plunged by 6% and its current market price is Rs 690. The BSE 500 is down by 1.4%. The top gainers in the BSE 500 Index are GMR INFRA (up 4.9%) and TCS (up 3.3%). The top losers are BIRLA CORP (down 5.7%) and PIRAMAL ENTERPRISES (down 5.3%).

The BSE HEALTHCARE Index Down 2% ; CAPLIN POINT Among Top Losers (Market Updates)

Sep 24, 2018 | Updated on Sep 24, 2018

The BSE HEALTHCARE Index Down at 15,697 (down 2.1%). Among the top losers in the BSE HEALTHCARE Index today are CAPLIN POINT, VIMTA LABS and PIRAMAL ENTERPRISES. Meanwhile, the BSE Sensex has plunged 1.2% to 36,946.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Sep 24, 2018 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 5-YR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS